PH 020 803
Alternative Names: PH-020-803Latest Information Update: 19 Jun 2023
At a glance
- Originator Suzhou Puhe Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer